Form 4: Scholar Rock Director Michael Gilman Acquires Shares and Options

Director Michael Gilman reports acquisition of Scholar Rock Holding Corp shares and options through restricted stock units and stock options.

Summary

• Michael Gilman, a director of Scholar Rock Holding Corp, reported changes in beneficial ownership on July 1, 2024.
• On June 27, 2024, Gilman acquired 13,500 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs will vest on the earlier of June 15, 2025, or the date of the Issuer's next Annual Meeting, contingent upon continued service.
• Gilman also acquired options to purchase 18,000 shares of common stock at an exercise price of $8.36, which will vest on the earlier of the first anniversary of the grant date or the date of the Issuer's next Annual Meeting, contingent upon continued service.
• Following these transactions, Gilman directly owns 13,500 shares through RSUs and indirectly owns 37,459 shares through a trust.
• He also directly owns options for 18,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The RSUs and stock options are subject to vesting conditions, indicating a long-term commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to monitor the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider trading activities.
• Similar filings are common across the biotechnology industry, with directors and officers regularly reporting transactions in their company's stock.
• Companies like Amgen, Biogen, and Gilead Sciences also have frequent Form 4 filings reflecting stock option exercises and share grants to executives and directors.

Stakeholder Impact

• The reported transactions provide stakeholders with insights into the actions of a key company director.
• These transactions can influence investor sentiment and potentially impact the company's stock price.

Key Dates